Background: Uroguanylin, originally isolated from urine, is a new natriuretic peptide. Its plasma level is increased in association with renal impairment and fluid retention in patients with renal diseases. Methods: Uroguanylin concentrations were measured in patients on hemodialysis (HD, n = 76) and those on continuous ambulatory peritoneal dialysis (CAPD, n = 10) using a sensitive ra- dioimmunoassay for human uroguanylin. Results: Plasma concentrations of immunoreactive (ir)-uroguanylin in the patients on HD and CAPD (212.0 ± 17.4 and 245.3 ± 39.5 fmol/ml) were significantly higher than the value for the normal controls (5.0 ± 0.3 fmol/ml). Plasma ir-uroguanylin levels before the start of regular HD were correlated with predialysis excess weight based on their dry weights (r = 0.33, p < 0.01) and with dialysis duration (r = 0.26, p < 0.05). The plasma levels in patients with HD, for whom high-flux membranes were used, were decreased at the end of regular HD as compared with the prior levels (p < 0.05), but not in those who underwent HD with conventional membranes. Conclusion: These findings suggest that the plasma ir-uroguanylin level is related to the patient’s volume status as well as renal impairment. Whether the accumulation of uroguanylin has a pathological effect has yet to be determined.

Keywords:
Uroguanylin, Hemodialysis, Continuous ambulatory peritoneal dialysis, Guanylate cyclase
1.
Greenberg RN, Hill M, Crytzer J, Krause WJ, Eber SL, Hamra FK, Forte LR: Comparison of effects of uroguanylin, guanylin, and Escherichia coli heat-stable enterotoxin STa in mouse intestine and kidney. J Invest Med 1997;45:276–283.
2.
Fonteles MC, Greenberg RN, Monteiro HS, Currie MG, Forte LR: Natriuretic and kaliuretic activities of guanylin and uroguanylin in the isolated perfused rat kidney. Am J Physiol 1998;275:F191–F197.
3.
Kinoshita H, Fujimoto S, Nakazato M, Yokota N, Date Y, Yamaguchi H, Hisanaga S, Eto T: Urine and plasma levels of uroguanylin and its molecular forms in renal diseases. Kidney Int 1997;52:1028–1034.
4.
Forte LR, Fan X, Harma FK: Salt and water homeostasis: Uroguanylin is a circulating peptide hormone with natriuretic activity. Am J Kidney Dis 1996;28:296–304.
5.
Miyazato M, Nakazato M, Yamaguchi H, Date Y, Kojima M, Kangawa K, Matsuo H, Matsukura S: Cloning and characterization of a cDNA encoding a precursor for human uroguanylin. Biochem Biophys Res Commun 1996;219:644–648.
6.
Hill O, Cetin Y, Cieslak A, Mägert HJ, Forssmann WG: A new human guanylate cyclase-activating peptide (GCAP-, uroguanylin): Precursor cDNA and colonic expression. Biochim Biophys Acta 1995;1253:146–149.
7.
Nakazato M, Yamaguchi H, Kinoshita H, Kangawa K, Matsuo H, Chino N, Matsukura S: Identification of biologically active and inactive human uroguanylin in plasma and urine and their increases in renal insufficiency. Biochem Biophys Res Commun 1996;220:586–593.
8.
Kinoshita H, Fujimoto S, Fukae H, Yokota N, Hisanaga S, Nakazato M, Eto T: Plasma and urine levels of uroguanylin, a new natriuretic peptide, in nephrotic syndrome. Nephron 1999;81:160–164.
9.
Kinoshita H, Nakazato M, Yamaguchi H, Matsukura S, Fujimoto S, Eto T: Increased plasma guanylin levels in patients with impaired renal function. Clin Nephrol 1997;47:28–32.
10.
Plum J, Grabensee B: Atrial natriuretic peptide in dialysis patients under various conditions of volume homeostasis. J Intern Med 1991;229:209–216.
11.
Shiota J, Kubota M, Hamada C, Koide H: Plasma atrial natriuretic peptide during hemodialysis with or without fluid removal. Nephron 1990;55:283–286.
12.
Yamamoto Y, Higa T, Kitamura K, Tanaka K, Kangawa K, Matsuo H: Plasma concentration of human atrial natriuretic polypeptide in patients with impaired renal function. Clin Nephrol 1987;27:84–86.
13.
Ando R, Matyuda O, Miyake S, Yoshiyama N: Plasma levels of human atrial natriuretic factor in patients treated by hemodialysis and continuous ambulatory dialysis. Nephron 1988;50:225–228.
© 2000 S. Karger AG, Basel
2000
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.